Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARGO BLOCKCHAIN PLC Regulatory Filings 2021

Apr 19, 2021

5008_rns_2021-04-19_7d67f914-0a7b-4321-b381-7c10034a28cf.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 9024V

Valereum Blockchain PLC

19 April 2021

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR")

VALEREUM BLOCKCHAIN PLC

("Valereum" or the "Company")

OTCQB UPDATE

London, UK, 19 April 2021 - Valereum Blockchain Plc (AQSE: VLRM), the Cryptocurrency Finance, Defi and Blockchain Technology venture builder, advises that the Company's US OTC Markets Sponsor, Galanopoulos & Company, has now submitted the application to OTC Markets in New York to facilitate the cross-trading of Valereum's ordinary shares onto the facilities of the OTCQB in the United States.

The Directors of Valereum Blockchain Plc take responsibility for this announcement.

The website address of the Company is  www.valereumblockchain.com.

END

Enquiries:

Valereum Blockchain Plc

Richard Poulden, Chairman

Tel: +44 7551 863 830

AQSE Growth Market Corporate Adviser

Peterhouse Capital Limited

Guy Miller / Allie Feuerlein

Tel: +44 (0) 207 469 0930

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXUKSRRAUUSAAR